Enterprise League logo

Product

SCY-770

BIOTECHNOLOGY

bySCYNEXIS, Inc.

United States (US)

ABOUT THE PRODUCT

SCY-770 is a novel, highly selective, clinical-stage direct AMPK activator under development as a new therapeutic approach for Autosomal Dominant Polycystic Kidney Disease (ADPKD). It directly activates AMPK, a key regulator of cellular metabolism, addressing the disease’s underlying metabolic abnormalities.

Information is owner-confirmed

Last updated 19 hours ago

Price range
N/A

Other products/services from SCYNEXIS, Inc.